DermaSensor Inc. has received FDA clearance for its real-time, non-invasive skin cancer evaluation system, making it the first AI-powered medical device capable of detecting all three common skin cancers: Melanoma, Basal Cell Carcinoma, and Squamous Cell Carcinoma. The system is designed to provide quantitative, point-of-care testing for primary care physicians in the U.S., potentially improving skin cancer detection in primary care settings. The approval allows the approximately 300,000 primary care physicians in the U.S. to use DermaSensor's AI-powered spectroscopy technology to evaluate suspicious moles, offering an immediate, objective result using an FDA-cleared algorithm.
The FDA pivotal study involved over 1,000 patients across 22 study centres, led by the Mayo Clinic, and demonstrated the device's high sensitivity of 96 percent across all 224 skin cancers. In a companion clinical utility study involving 108 physicians, the DermaSensor device was found to decrease the number of missed skin cancers by half, increasing accuracy and confidence in assessing cancerous lesions. The technology aims to empower primary care physicians, who play a critical role in early disease identification, especially in areas with limited access to dermatology services.
DermaSensor's AI-powered device is expected to enhance collaboration between primary care and dermatology, enabling better-prioritised referrals and potentially benefiting both types of healthcare professionals. The device's clearance by the FDA marks a significant milestone in improving skin cancer detection and addressing the challenges associated with access to dermatology, particularly in rural areas.
Click here to read the original news story.